It's shaping up to be another day of losses on the U.S. exchanges, thanks to disappointing retail sales and ugly earnings from a blue-chip tech titan. Among the equities in focus are retailer J C Penney Company Inc (NYSE:JCP), pharmaceutical interest Mylan NV (NASDAQ:MYL), and genetic analysis issue Illumina, Inc. (NASDAQ:ILMN).
ILMN is up 5.5% this morning, last seen trading at $163.90, on the news that the stock will be listed on the S&P 500 Index (SPX) as of next Wednesday's close, replacing Sigma-Aldrich Corporation (NASDAQ:SIAL). Illumina, Inc. shares fell to an annual low of $130 in early October, after the company issued lackluster guidance, but have rebounded 26.1% since then. Option buyers have turned bullish over the last several weeks, as ILMN's 10-day call/put volume ratio on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) sits at 3.62 -- higher than 94% of readings from the past year.
Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!